CYTOMEDIX, INC.

FOR IMMEDIATE RELEASE -- NEW SENIOR MANAGEMENT TEAM AND STOCK TICKER SYMBOL

Little Rock, Arkansas *****CDT, April 6, 2000

Cytomedix, Inc. (formerly, Autologous Wound Therapy, Inc.) today announced the
appointment of new executive management personnel.

Dennis Hendren, acting as Board Chairman and speaking on behalf of the company,
said, "We are delighted to announce that an experienced team of healthcare
executives have agreed to join Cytomedix to act as the company's new senior
management team. Each of these individuals brings to the company a breadth of
talent and many years of experience in the biomedical field. We are very much
looking forward to their plans to expand the base of our successful and growing
AuToloGel(TM) wound therapy business and develop for the company new
opportunities in other areas of cellular therapies and molecular biotechnology."
Each of the new managers has been previously employed by Baxter International
Inc.

JAMES A. COUR, PRESIDENT AND CEO - Mr. James A. Cour will assume the position
of President and CEO. Before joining the company, Mr. Cour served nineteen
years with Baxter International in a variety of management positions, most
recently as its Vice President of Portfolio Strategy. He previously served as
General Manager of Operations at Baxter Limited (a $725 million Japanese
operating subsidiary) and Director of Business Development for Baxter's Global
Business Group. Mr. Cour received an MBA degree from the University of Chicago
Graduate School of Business, with a specialization in Finance. He received a
Bachelor of Business Administration Degree from the University of Notre Dame,
graduating with honors. Mr. Cour will provide overall leadership to the company
and particular expertise in the area of biomedical technology analysis, mergers
and acquisitions and strategic planning.

ROBIN L. GELLER, VICE PRESIDENT OF SCIENCE & TECHNOLOGY - Dr. Geller also joins
the company from Baxter Healthcare where she has served in a variety of
capacities including Senior Assessment Manager for Corporate Quality Systems
and Senior Research Scientist for the Gene Therapy Division. Before joining
Baxter, Dr. Geller was on the faculty of the University of Minnesota in the
departments of Laboratory Medicine & Pathology and Pediatrics where she also
did post-doctoral research in cellular immunology. She has authored 31
scientific papers, is the principal or co-inventor of seven issued or pending
patents, and is on the editorial board of or a reviewer for three scientific
journals. She received her doctoral degree in Molecular Biology from the
University of Wisconsin and a Bachelor of Science Degree in Genetics from the
University of California at Berkeley. Dr. Geller will be in charge of the
regulatory affairs of the company and will be responsible for identifying
emerging technologies, and performing scientific due diligence.

CHRISTOPHER J. CAYWOOD, VICE PRESIDENT OF STRATEGY & BUSINESS DEVELOPMENT - Mr.
Christopher J. Caywood joined Baxter Healthcare in 1998 and worked as Director
of Business Planning and Development. Previously, he served in various
financial and legal capacities for





Sears, Roebuck and Co. including Director of Financial Analysis, Manager of
Competitive and Economic Analysis, and Tax Attorney. Before joining Sears, he
practiced law for seven years with firms in Boston and Chicago. He has a
Master's Degree in Business Administration from the University of Chicago
Graduate School of Business, a Juris Doctor Degree, Master's Degree in World
Politics, and a Bachelor's Degree in History, with High Honors and Distinction,
all from the University of Michigan. Mr. Caywood will be responsible for
formulating the long-term business strategy of the company and for
identification, negotiation, and execution of acquisitions and licensing
transactions.


DAVID C. DEMAREST, VICE PRESIDENT, GENERAL COUNSEL & CORPORATE SECRETARY - Mr.
David C. Demarest joins the company following three years of private law
practice with the firm of Preston, Gates & Ellis. There, he specialized in
biotechnology and pharmaceutical transactions, high-technology research &
development projects, domestic and international licensing; transnational
investment and corporate compliance. Before this private practice, he spent 13
years as in-house counsel for Baxter International, serving on extensive
expatriate assignments in Brussels, Tokyo, and Singapore. Mr. Demarest holds a
Masters of Laws Degree from Harvard Law School, a Bachelor of Laws Degree, with
honors, from McGill University Faculty of Law, and a Bachelor of Arts degree,
with honors, from Colgate University. Mr. Demarest is fluent in French and
Japanese. As general counsel Mr. Demarest will be responsible for managing the
legal affairs of the corporation, instituting a rigorous corporate compliance
program, supervising the maintenance of the books and records of the corporate
entity, and general administration of the company's affairs.

Mr. Cour said, "We are all very pleased to be joining Cytomedix. The
AuTolo(TM)Cure process developed in Little Rock has tremendous potential, both
in the treatment of chronic wounds and other medical applications. The new
management brings a wealth of experience and a diverse set of skills to
supplement the excellent team that Dennis Hendren and his colleagues have
already built. We believe the company is well-positioned to take a leadership
role in the rapidly expanding field of cellular therapies."

The company's current ticker symbol, "AWTX" (NASDAQ OTC:BB) will be changed to
"CYDX," effective at the start of trading on April 7, 2000. The company will
also relocate its corporate headquarters to Suburban Chicago in the near
future, while maintaining its current offices in Little Rock.

Cytomedix is the proprietary owner of the AuTolo(TM)Gel and AuTolo(TM)Cure
processes, used in the treatment of chronic wounds such as diabetic
neuropathies, and venous stasis and decubitus ulcers.

For further information, please contact: Dennis Hendren at (501) 225-8400.


                                       2